Rep. Robert Bresnahan, Jr. Sells IQVIA Holdings Inc. (NYSE:IQV) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

IQVIA Price Performance

Shares of NYSE IQV opened at $177.27 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $31.25 billion, a PE ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a one year low of $176.03 and a one year high of $253.84. The firm has a fifty day moving average of $193.15 and a 200 day moving average of $206.47.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently bought and sold shares of the company. Private Trust Co. NA increased its position in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co grew its position in shares of IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. lifted its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares during the last quarter. Finally, Cypress Wealth Services LLC lifted its position in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 57 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.